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ABSTRACT 
DEVELOPMENT AND EVALUATION OF VACCINE CANDIDATES FOR 
SENECAVIRUS A  
BISHWAS SHARMA 
2019 
Senecavirus A (SVA) has been associated with several outbreaks of vesicular disease (VD) 
since 2014 in major swine-producing countries around the world. The virus causes VD that 
is clinically indistinguishable from foot-and-mouth disease (FMD) in pigs. Currently there 
are no commercial vaccines available for SVA. Here, we developed a live attenuated SVA 
strain by mutating a wild type SVA strain SD15-26 (wt SVA). The live attenuated virus, 
rSVA mSacII, replicated less efficiently in cell cultures in vitro and expressed lower 
amounts of VP1 and VP2 capsid proteins than wt SVA. Most importantly, the rSVA 
mSacII virus failed to induce clinical signs in experimentally infected pigs. Additionally, 
animals inoculated with rSVA mSacII presented lower levels of viremia, virus shedding 
and viral load in tissues than wt SVA. Notably, despite its attenuated phenotype animals 
inoculated with rSVA mSacII developed similar virus neutralizing antibody responses to 
those animals inoculated with the wt SVA. This led us to assess the immunogenicity and 
protective efficacy of the rSVA mSacII virus. For this, the rSVA mSacII was either 
inactivated with aziridine compound binary ethyleneamine (BEI) to be used as an 
inactivated or used as a live vaccine administered via the intramuscular (IM) or intranasal 
(IN) routes. An animal experiment was conducted consisting of four groups each 
containing 6 pigs: control group was sham-immunized with plain RPMI-1640; inactivated 
group was immunized with 106 TCID50 of BEI inactivated virus; live IM group was 
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immunized with 106 TCID50 of live rSVA mSacII via IM route; and live IN group was 
immunized with 106 TCID50 of live rSVA mSacII via the IN route. None of the immunized 
animals developed clinical signs nor lesions of SVA. RT-qPCR was performed on serum, 
oral, nasal and rectal swabs to assess viremia and virus shedding. Live immunized animals 
were viremic and shed virus, decreasing gradually after 7-14 days post-immunization. SVA 
specific virus neutralizing antibodies began to appear 3-5 days pi in live group and 14 days 
pi in inactivated group. The peak titer of inactivated vaccine was, however, lower than live 
vaccinated group even after a booster immunization at 21 days pi. After PBMC recall 
stimulation by UV inactivated SVA and recombinant SVA-VP2 protein, we observed 
higher proliferation of CD4+, CD8+ and CD4+CD8+ T cells in live vaccinated groups than 
other groups. At 42 days pi, challenge with 108.5 TCID50 of a heterologous SVA strain was 
performed and the protective efficacy of the rSVA mSacII virus evaluated. We observed 
clinical signs and vesicular lesions characteristic of SVA in control and inactivated group 
four days post-challenge. None of the animals in live vaccinated group displayed any 
clinical signs. Both live vaccinated groups presented lower levels of viremia and shed less 
virus than control group, however, level the of viremia and virus shedding in inactivated 
group was similar to control group. Viral load in tissues including tonsil, mediastinal and 
mesenteric lymph nodes were also assessed. Similar to virological findings in serum and 
secretions, viral loads in tissues were also lower in live vaccine groups when compared to 
control and inactivated groups. A negative correlation was observed between viremia/virus 
shedding with neutralizing antibody titer and with percentage proliferative CD4+, CD8+ 
and CD4+/CD8+ T cells. Similar negative correlation was observed between viral load in 
tissues with neutralizing antibody titer and with percentage proliferative CD8+ and 
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CD4+/CD8+ T cells. These findings show that live vaccination by rSVA mSacII protects 
against SVA challenge and the vaccine candidate has potential as a tool to control SVA 
infection. 
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Senecavirus A 
Senecavirus A (SVA) is only species of genus Senecavirus in family Picronaviridae 
(1). The virus is small (about 30 nm) and lacks an envelope. It is icosahedral in shape which 
is formed from 60 protomers of four polypeptides (VP1-4) (2).  
SVA contains positive sense single stranded RNA as genome consisting of about 
7.2 kb. The genome has a single open reading frame (ORF) which translates to a single 
polyprotein precursor of 2181 amino acids. The polyprotein of SVA is in L-P1-P2-P3 
arrangement (3). The leader protein (L) does not have catalytic residues for proteolytic 
activity which is commonly found in other picornaviruses. The P1 polypeptide is cleaved 
by 3C protease of the virus to give VP0, VP3 and VP1, where VP0 is later cleaved to VP2 
and VP4. These proteins organize to form capsid proteins. P2 is cleaved to form 2A, 2B 
and 2C proteins. 2A is predicted to perform ribosome skipping function (3). A possible 
role of 2B is to act as viroporins that enhance membrane permeability leading to formation 
of intracellular virus replication vesicles (4). 2C protein is involved in RNA synthesis (5). 
P3 is cleaved to 3A, 3B, 3C protease and 3D polymerase. Less is known about 3A, but it 
contains a putative transmembrane α-helix (3). 3B encodes genome linked VPg (6). 3C is 
a proteinase (7) which is conserved among other picornaviruses and 3D is major 
component of RNA-dependent RNA polymerase (RdRp) (8). This virus closely resembles 
the genus Cardiovirus based on P1, 2C, 3C and 3D genome regions but is different than 
other picornaviruses based on other genome portions (3). Moreover, based on crystal 
Chapter 1: Literature Review 
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structure, the VP1 subunit shows maximum variation and VP2 shows minimum variation 
compared with other members of Picornaviridae (2).  
Epidemiology 
Pigs are supposed to be the natural host for Senecavirus A. Serological studies have 
found the presence of SVA specific antibodies in pigs, cattle and mice. RNA of SVA has 
been detected in houseflies collected from pig farms while the virus has been isolated from 
pigs, mouse feces, mouse small intestine and environmental samples (9). This finding 
might hint that houseflies and mice are involved in SVA transmission, but further evidence 
is required to prove it.  
Swine idiopathic vesicular disease (SIVD) has been reported in pigs in Australia 
(10), New Zealand (11),  Canada (12) and United States (13). However, association of SVA 
with SIVD was first determined in hogs originating from Manitoba at a Minnesota harvest 
facility (12).  
SVA was identified only in Canada and the US before 2014 and it is believed that 
SVA had been circulating in the US since 1988 (14). During late 2014, an outbreak of SVA 
was reported in Brazil which caused 30-70% neonatal mortality in pigs (15). More 
outbreaks were reported in six states from three geographical regions of Brazil in 2015 
(16). In the same year, 109  cases of SVA were reported in sows and growing pig farms 
from the Midwest region of the US (17, 18). Sequence analysis of SVA from outbreak in 
Canada in 2015 and other countries determined there was 9.96 × 10-3 nucleotide 
substitutions per site per year (19) which is among highest in picronaviruses (20). China 
also reported its first outbreak of SVA in sows and neonatal piglets in March, 2015 and 
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this strain shared 94-97% sequence identity with SVA strains of US origin (21). Colombia 
reported its first SVA outbreak in February 2016 and sequence identity was more similar 
(98.5-99.8%) to US strains. In the same year, Thailand reported its first SVA outbreak, 
where its identity was more similar (98.2%) to Canadian strains (22). More outbreaks are 
recorded in recent years in the US (23), China (24) and Brazil (25). These outbreaks suggest 
requirement of additional surveillance and research work to understand evolution and 
epidemiology of SVA. 
Pathogenesis and immune response 
Senecavirus causes acute, self-limiting vesicular lesions in pigs which are very 
similar to those in foot and mouth disease (FMD), swine vesicular disease and vesicular 
stomatitis (16, 26). Vesicular lesions are observed in snout, coronary bands and interdigital 
spaces and animals present lameness, anorexia and lethargy (16, 26, 27). Clinical signs are 
observed for 4 to 14 days pi and viremia is observed for 3 to 10 days pi (28).  
SVA is detected in liver, lungs, lymph nodes, spleen, small and large intestine and 
tonsil of infected pigs 3 days post-infection, with higher level in tonsils. Virus shedding 
can be observed till 28 days pi in oral, nasal secretions and feces (26). Another study found 
viremia at 3 days pi and lesions at 4 days pi (27). In another study in China by a different 
SVA strain, pigs showed lesion and viremia two days post-challenge (29).  Neonatal 
mortality has also been observed due to SVA infection in piglets aged up to 7 days (30). 
The infected piglets present petechial hemorrhages of kidneys, ballooning degeneration of 
the transitional epithelium of the urinary bladder, villious atrophy of small intestine, 
interstitial pneumonia, ulcerative lesion in tongue and coronary bands (31); however, 
experimental studies with such observation have not been observed till now. In 15-week 
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old finishing pigs, histopathological changes in tonsils, spleen and lymph nodes involved 
lymphoid hyperplasia while lungs presented multifocal atelectasis and occasional 
congestion during acute infection. However, only tonsil displayed moderate lymphoid 
hyperplasia on day 38 pi on same study (26). 
Recent studies indicate SVA infection induces early immune response. 
Seroconversion occurs approximately 5 days post infection (26, 30). Increasing 
neutralizing antibody (NA) titer occurs leading to reduction in disease severity, viremia, 
viral load in tissue, and viral shedding in body secretions indicating antibody response to 
clear virus from circulation (26, 28). The early NA mostly constitutes IgM antibodies 
which are mainly directed against VP2 and VP3 proteins of virus. IgM level falls 14 days 
pi and undetectable after 35 days. IgG response against VP1 and VP3 also follows a similar 
trend but does not correlate with early neutralizing activity against the virus (28). 
Regarding cell mediated immune response, it has been observed that interferon-
gamma (IFN-γ) expressing CD4+ T cell was high at 7 days pi and increased until day 14 
pi. Moreover, IFN- γ expressing CD8+ and double positive CD4+CD8+ T cells increased 
after day 10 pi. Furthermore, it was found that SVA induced memory T cell response which 
responded to recall stimulation in vitro (28). Similar T cell response has been found among 
unrelated SVA strains (32). These findings give insight on virus pathogenesis and host 
response against the virus; however additional studies are required to improve our 
understanding in this field.  
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Vaccination and control 
Research is limited on specific control measures to limit SVA transmission, 
however sanitary practices and biosecurity measures can be adopted in pig farms similar 
to other infectious agents. Among household bleach, a phenolic disinfectant and a 
quaternary ammonium-aldehyde disinfectant tested against SVA, 1:20 dilution of bleach 
with contact time of 10-15 minutes was found to be most effective  (33). Moreover, a 1:20 
dilution of  accelerated hydrogen peroxide (AHP®) based disinfectant and 1% Virkon® 
with 10 minutes contact time were effective against wet films of SVA (34).  
No commercial vaccine or specific treatments are available for SVA infections. An 
inactivated vaccine against SVA using binary ethyleneamine was developed and evaluated 
recently which displayed protective efficacy against the virus challenge in a dose 
dependent manner (29). Inactivated vaccines are widely used against FMD mostly using 
BEI for inactivation (35). However, the problem of incomplete inactivation of virulent 
virus, cross-serotype protection and long-life protection remains (36). Similar problems 
might be observed in inactivated SVA vaccine as it is closely related to FMD virus.  
To address the problems of vaccine unavailability, we developed live and 
inactivated vaccines against SVA and tested their immunogenicity and protective efficacy 
in pigs. 
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The overall goal of our study was to develop a vaccine against Senecavirus A (SVA). The 
objectives of our study were: 
Objective 1: To develop live and inactivated vaccines against SVA. 
To achieve this objective, we developed a infectious clone of SVA derived from SVA 
SD15-26 strain. Specific mutations were added on wild type sequence to attenuate the 
virus. In-vitro and in-vivo studies were carried out to determine the attenuation of 
recombinant virus. The same virus was also inactivated using Binary ethyleneamine and 
mixed with adjuvant to prepare an inactivated vaccine. 
Objective 2: To assess immunogenicity of live vaccine and inactivated vaccine and 
protective efficacy in pigs after heterologous SVA challenge. 
To achieve this objective, pigs were immunized with the vaccine candidates and challenged 
with a heterologous strain. Clinical signs, viremia, virus shedding, viral load in various 
tissue, humoral and cell-mediated immune responses were assessed in pigs.  
The results of both studies are presented in Chapter 2 of this thesis. 
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Abstract  
Senecavirus A (SVA) is an emerging picornavirus causing vesicular disease (VD) clinically 
indistinguishable from foot-and-mouth disease (FMD) in pigs. Notably, there are no 
vaccines currently available for SVA. Here we developed a recombinant SVA strain 
(rSVAm SacII) using reverse genetics and assessed its immunogenicity and protective 
efficacy in pigs. In vivo characterization of the rSVAm SacII strain demonstrated that the 
virus is attenuated, as evidenced by absence of lesions, decreased viremia and virus 
shedding in inoculated animals. Notably, while attenuated, rSVA mSacII virus retained its 
immunogenicity as high neutralizing antibody (NA) responses were detected in inoculated 
animals. To assess the immunogenicity and protective efficacy of rSVA mSacII, four-
week-old piglets were sham-immunized or immunized with inactivated or live rSVA 
mSacII virus-based formulations. A single immunization with live rSVA mSacII virus via 
the intramuscular (IM) and intranasal (IN) routes resulted in robust NA responses with 
antibodies being detected around days 3-7 pi. Neutralizing antibody responses in animals 
immunized with the inactivated virus via the IM route were delayed and only detected after 
a booster on day 21 pi. Immunization with live virus resulted in recall T cell proliferation 
(CD4+, CD8+ and CD4+/CD8+ T cells), demonstrating efficient stimulation of cellular 
immunity. Notably, a single dose of the live attenuated vaccine candidate resulted in 
protection against heterologous SVA challenge, as demonstrated by absence of overt 
disease and reduced viremia, virus shedding and viral load in tissues. The live attenuated 
vaccine candidate developed here represents a promising alternative to prevent and control 
SVA in swine. 
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Importance 
The relevance of Senecavirus A (SVA) lies on its clinical similarity to foot-and-mouth 
disease (FMD) and other high-consequence vesicular diseases of swine. The lack of 
vaccines for SVA, hinders disease control strategies and allows continuous virus 
circulation in the field posing significant challenges to official veterinary services. In the 
present study, we developed an attenuated SVA strain and demonstrated its 
immunogenicity and protective efficacy in pigs. A single dose of the live attenuated 
vaccine candidate administered intramuscularly (IM) or intranasally (IN) to pigs elicited 
robust humoral and T cells responses and provided protection against heterologous SVA 
challenge. Protection afforded by the live vaccine candidates was evidenced by lack of 
clinical signs and lesions following challenge and decreased levels of viremia, virus 
shedding and viral load in tissues. This vaccine candidate represents a good alternative to 
control SVA infection and disease. 
Keywords: SVA, Seneca Valley virus, live attenuated vaccine, inactivated vaccine 
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Introduction 
Senecavirus A (SVA) is a vesicular disease (VD)-causing pathogen of pigs and the 
only species of the genus Senecavirus in the family Picornaviridae (1). SVA is a non-
enveloped, icosahedral virus with a single-stranded positive sense RNA genome with 
approximately 7.2 kb. The SVA genome encodes a unique open reading frame (ORF), 
which is proteolytically processed in four structural proteins (VP1-VP4) and eight non-
structural proteins (L, 2A–2B–2C–3A–3B–3C–3D) (2). The virus genome is organized in 
a central coding region (ORF1) flanked by 5’- and 3’-untranslated regions (UTRs) and a 
poly(A) tail following the 3’-UTR (2).  
Senecavirus A was first identified as a contaminant of human fetal retinal cells 
(PER.C6) in the US in 2002 (3). Retrospective sequencing of archived picorna-like viruses 
at the United States Department of Agriculture National Veterinary Service Laboratories 
(NVSL), revealed the circulation of SVA in the US swine population since at least 1988 
(3). Since its first description in 2002, SVA has been explored as an oncolytic agent for 
cancer treatment in humans (4–6). Recently the virus gained importance in the veterinary 
field due to the increased incidence of SVA-induced VD in pigs. Since 2014, SVA has 
been associated with VD outbreaks in swine in Canada (7), the US (2, 8–10), Brazil (9, 11, 
12), Colombia (13), China (14), Thailand (15) and Vietnam (16). Pigs are thought to be the 
main reservoir for SVA; however, the virus has been also isolated from mice, and its 
nucleic acid has been detected in houseflies collected in SVA affected and non-affected 
farms (9). Additionally, neutralizing antibodies against SVA have been detected in pigs, 
cattle and mice (3). The importance of these species for the epidemiology of SVA, 
however, remains unknown.  
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The clinical relevance of SVA, lies on its similarity with other high-consequence 
VDs of swine, including FMD, swine vesicular disease (SVD), vesicular stomatitis (VS) 
and vesicular exanthema of swine (VES) (12). Infection with SVA likely occurs via the 
oral and/or respiratory routes and after an incubation period of 3 to 5 days, clinical signs 
including lethargy and lameness are observed. The clinical signs are followed by 
development of vesicles on the snout and/or feet (dewclaw, coronary band and sole) of 
affected animals (17). The lesions are characterized by cutaneous hyperemia which 
progresses into fluid-filled vesicles. As the disease progresses, the vesicles rupture and 
evolve into skin erosions that eventually scab and resolve within 12-16 days post-infection 
(pi) (17–19). A short-term viremia (1-10 days post-infection, pi) occurs in infected animals 
and the levels of viremia decline as serum neutralizing antibody (NA) levels rise (18). 
The immune responses to SVA are characterized by the development of early and 
robust NA titers (17, 18, 20), which are strongly correlated with VP2- and VP3-specific 
IgM responses within the first week of infection (18). Notably, NA levels parallel with 
decreased viremia and resolution of the disease (18). Analysis of the major porcine T cell 
subsets revealed that during the acute/clinical phase of SVA infection (14 days pi) T cell 
responses are characterized by an increased frequency of αβ T cells, especially CD4+ T 
cells that are initially detected by day 7 pi and increase in frequency until day 14 pi. 
Additionally, the frequency of CD8+ and double-positive CD4+CD8+ T cells 
(effector/memory T cells) expressing IFN-γ or proliferating in response to recall SVA 
stimulation increases after day 10 pi (18). These observations indicate that SVA elicits B 
and T cell activation early upon infection, with IgM antibody levels being associated with 
early neutralizing activity against the virus and peak B and T-cell responses paralleling 
12 
 
with clinical resolution of the disease, suggesting that both arms of the immune system 
may contribute to the control of SVA infection. Importantly, there is only one known 
serotype of SVA (2, 21) and genetically diverse viral strains present cross neutralizing- and 
cross T-cell responses (21).   
 Currently there are no vaccines available for SVA. A recent study assessed the 
immunogenicity of an inactivated SVA vaccine candidate, demonstrating protection 
against homologous virus challenge (22). The most effective picornavirus vaccines consist 
of inactivated or live attenuated vaccines. Most vaccines used for FMDV, for example, are 
inactivated; however, they fail to induce long-term protection requiring annual re-
vaccinations (23). Poliovirus (PV) vaccines long used in humans, leading to the eradication 
of wild type poliovirus, were either inactivated poliovirus vaccine (IPV) or live oral 
poliovirus vaccine (OPV). The live OPV induces long-lasting mucosal immunity against 
PV. In this study we generated a recombinant attenuated SVA strain based on a 
contemporary SVA isolate (17) and assessed the immunogenicity and protective efficacy 
of inactivated or live virus formulations against heterologous SVA challenge. 
Results 
Generation and in vitro characterization of recombinant SVA. Recently we have developed 
a cDNA clone for SVA strain SD15-26 (Fernandes et al., unpublished data). This clone 
was used here to develop a second recombinant SVA, originally designed to facilitate the 
differentiation of the rSVA virus from the parental wt SVA strain. In this clone, we 
introduced four additional nucleotide changes in the rSVA genome. Three of those changes 
are located in the 5’UTR (c→t, positions 28, 31 and 32) and the fourth change consists of 
a silent nt change (c→a) at position 942 (VP4 coding region) of the rSVA genome (added 
13 
 
to delete a SacII restriction endonuclease site). A synthetic DNA fragment containing these 
nucleotides changes was cloned into the backbone of the rSVA plasmid (virus described 
above; pBrick-FLSVA-SD15-26) using unique restriction endonucleases (NheI and SfiI) 
and standard cloning techniques. The resultant recombinant SacII mutant virus (rSVA 
mSacII) was rescued by transfection of in vitro transcribed viral genomic RNA into BHK-
21 cells, followed by amplification of the recombinant virus in the highly permissive 
H1299 cells. The identity of the rSVA mSacII was confirmed by sequencing and restriction 
digestion with SacII (Fig. 1A) and its replication properties were compared to the wt SVA 
virus in vitro. Notably, multi-step growth curves revealed an impaired replication of rSVA 
mSacII virus when compared to wt SVA, as evidenced by significantly lower viral yields 
in rSVA mSacII infected cells (~1 log after 8 h post-inoculation; P < 0.001) (Fig. 1B and 
C). Additionally, expression levels of two of the main SVA capsid proteins (VP1 and VP2) 
were compared between wt SVA and rSVA mSacII viruses. As shown in Fig. 1D and 1E, 
the levels of VP1 and VP2 protein detected in rSVA mSacII infected cells were markedly 
lower when compared to the levels of those proteins detected in wt SVA infected cells.  
The rSVA mSacII virus is attenuated but retains its immunogenicity in pigs. The 
pathogenicity of the rSVA mSacII virus was compared to that of the wt SVA strain in pigs. 
For this, twelve SVA-negative 15-week old finishing pigs (~60 kg) were randomly 
allocated into two groups (G1: wt SVA, n = 6; and G2: rSVA mSacII , n = 6), inoculated 
oronasally (1/2 orally and 1/2 intranasal) (17) with the corresponding virus, and monitored 
for clinical signs and characteristic SVA lesions for 14 days. Notably, while all pigs 
inoculated with the wt SVA strain SD15-26 presented characteristic clinical signs 
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(lethargy, lameness) and lesions (vesicles on the snout and/or foot) of SVA infection, none 
of the rSVA mSacII-inoculated animals developed overt clinical disease (Fig. 2A and 2B). 
Viremia, virus shedding (oral and nasal secretions and feces) and viral load in 
tissues were also evaluated. Levels of viremia and virus shedding were significantly lower 
in rSVA mSacII -inoculated animals when compared to wt SVA-inoculated animals (Fig 
2C-F). Additionally, viral load in tissues was markedly reduced in rSVA mSacII-inoculated 
animals when compared to wt SVA-inoculated animals (Fig. 3A). Notably, NA responses 
were similar in rSVA mSacII- and wt SVA-inoculated animals (Fig. 3B). Together these 
results indicate that the attenuated rSVA mSacII is highly immunogenic in pigs. 
Clinical and virological findings following immunization with inactivated or live rSVA 
mSacII virus. Clinical and virological parameters were evaluated following immunization 
of weaned piglets with inactivated or live attenuated rSVA mSacII virus. Twenty-four 4-
week old SVA-negative piglets were randomly allocated into four experimental groups as 
follows: Group 1, control sham-immunized (n = 6, RPMI 1640 medium, intramuscular 
[IM]), Group 2, inactivated rSVA mSacII  (n = 6, IM), Group 3, live attenuated rSVA 
mSacII  (n = 6, IM) and Group 4,  live attenuated rSVA mSacII  (n = 6, intranasal [IN]). 
Animals from control (G1) and inactivated (G2) groups were immunized on days 0 and 21, 
whereas animals from the live IM (G3) and live IN (G4) groups received a single dose 
immunization on day 0. A detailed experimental design including vaccine dose and route 
of immunization are presented in Table 1. The inactivated vaccine preparation consisted of 
a binary ethyleneimine (BEI)-inactivated rSVA mSacII virus suspension (106 tissue culture 
infectious dose 50 [TCID50/mL]) in a water-in-oil-in-water (W/O/W) adjuvant emulsion 
(Montanide ISA 201 VG; 1:1). The live attenuated virus preparation consisted of a rSVA 
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mSacII virus suspension (106 TCID50) in RPMI 1640 medium. Western blot analysis of the 
candidate vaccine preparations demonstrated similar antigen loads for two of the major 
SVA capsid proteins VP1 and VP2 in both inactivated and live attenuated virus 
preparations (Fig. 4). Following immunization, all animals were monitored daily for 
characteristic SVA clinical signs and vesicular lesions (21). No clinical signs nor lesions 
were observed in any of the immunized animals (Fig. 5A). As no gross lesions were 
observed, clinical scores remained 0 for all groups during the post-immunization (pi) phase 
of the experiment (Fig. 5B).  
The levels of viremia were assessed in serum samples collected on days 0, 3, 5, 7, 
14 and 21 pi by using a SVA real-time reverse transcriptase PCR (RT-qPCR). No viremia 
was detected in control (G1) and inactivated rSVA mSacII (G2)-immunized animals (Fig. 
5C). Whereas SVA RNA was detected in serum from both live rSVA mSacII IM (G3) and 
IN (G4) immunized groups. Animals in G3 and G4 presented viremia between days 3 and 
7 pi with all animals being negative from day 14 pi onwards (Fig. 5C). 
Virus shedding was assessed in oral and nasal secretions and feces. Oral, nasal and 
rectal swabs collected on days 0, 3, 5, 7, 14 and 21 pi were tested by RT-qPCR. Virus 
shedding was detected up to day 14 pi on oral secretions or up to day 14-21 pi on nasal 
secretions and feces of animals in the live IM (G3) and live IN (G4)-vaccine groups, 
respectively (Fig. 5D-F). No virus excretion was detected on control (G1) and inactivated 
(G2) groups (Fig. 5D-F). Animals immunized with the live rSVA mSacII via the IN route 
(G4) presented significantly lower levels of virus shedding when compared to animals in 
the live IM group (G3) in oral and nasal secretions and in feces (Fig. 5D, 5E and 5F). 
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Immunogenicity of inactivated or live rSVA mSacII virus in pigs. The immunogenicity of 
inactivated or live rSVA mSacII virus was evaluated. Humoral immune responses were 
assessed by virus neutralization assays (9, 18) in serum samples collected on days 0, 3, 5, 
7, 14, 21, 28 and 35 pi. Immunization with live rSVA mSacII virus via the IM (G2) and IN 
(G3) routes, elicited robust NA responses with high antibody titers being detected as early 
as day 3 pi in animals in the live IM group (G3) (Fig. 6A). Interestingly, early NA titers 
elicited by live IM immunization were significantly higher than antibody titers elicited by 
IN immunization (day 5-7 pi; P < 0.01), whereas no differences in NA titers in the live IM 
and IN immunized groups were observed after day 14 pi (Fig. 6A). Notably, a single dose 
of the live rSVA mSacII administered either by the IM or IN routes resulted in significantly 
higher NA responses when compared to immunization with the inactivated virus 
formulation, even after the booster immunization on day 21 pi (Fig. 6A, days 3-35 pi; P < 
0.01). No NA antibodies were detected in control sham-immunized animals (G1) prior to 
challenge infection (days 0-35 pi) (Fig. 6A). 
 T cell responses elicited by immunization with rSVA mSacII virus were evaluated 
by lymphocyte proliferation assays. Peripheral blood mononuclear cells (PBMCs) 
collected on day 42 pi (day of challenge) were subjected to in vitro recall stimulation with 
SVA or with recombinant SVA-VP2 protein as previously described (18). Interestingly, 
significant recall T cell (CD3+) proliferation was detected in animals immunized with live 
rSVA mSacII via the IM (G3) and IN (G4) routes (P < 0.05). Additionally, proliferative 
recall responses of individual T cell subsets, including CD4+, CD8+, double positive 
CD4+/CD8+ and γδ T cells (double negative CD4-/CD8- cells) were also significantly 
higher in animals in the live IM (G3) and live IN (G4) groups (P < 0.05) (Fig. 6B). A 
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similar trend in recall T cell proliferation was observed in animals immunized with live 
virus and re-stimulated with recombinant VP2 protein (Fig. 6C). 
Immunization with rSVA mSacII protects against heterologous SVA challenge. The 
protective efficacy of inactivated or live rSVA mSacII virus were evaluated following 
challenge infection with a heterologous contemporary SVA strain. All immunized animals 
were challenged oronasally with a virulent SVA strain SVA MN15-84-22 (9) on day 42 
post-immunization (Table 1). Animals were monitored daily for characteristic SVA 
clinical signs and lesions and total daily clinical scores were calculated as previously 
described (21). All animals in control sham immunized G1 presented clinical signs and/or 
lesions of SVA starting on day 4 post-challenge (pc). Animals presented lethargy and 
lameness and four of six animals (4/6) displayed characteristic vesicular lesions (Fig. 7A). 
Additionally, 3/6 (50%) animals in the inactivated G2 developed lameness and 
characteristic VD (Fig. 7A). Similar to control animals, G2 animals developed lesions on 
or after day 4 pc (Fig. 7A and B). Notably, a single dose of the live rSVA mSacII via the 
IM (G3) or the IN (G4) routes resulted in complete protection from clinical SVA, as no 
clinical signs nor lesions were observed in immunized animals (Fig 7A and B). Peak 
clinical scores were observed on day 6 pc in control animals or on day 9 pc in the 
inactivated vaccine group (Fig. 7B). As no gross lesions were observed in both live vaccine 
groups (G3 and G4), clinical scores for these groups remained 0 throughout the challenge 
phase of the experiment (Fig. 7B). 
The levels of viremia were also assessed post-challenge infection. Serum samples 
collected on days 0, 3, 7, 10 and 14 pc were tested for SVA RNA by RT-qPCR. SVA 
viremia was detected in control sham-immunized (G1) and in the inactivated group (G2) 
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animals between days 3 and 10 pc (Fig. 7C). Notably, the levels of viremia in animals 
immunized with live rSVA mSacII IM and IN were significantly lower than in control- and 
inactivated rSVA mSacII-immunized animals (Fig 7C, P < 0.01). In fact, only a few 
animals immunized with live rSVA mSacII IM (2/6) and IN (3/6) presented viremia on day 
3 or 7 pc, respectively (data not shown).  
Virus shedding was assessed in oral and nasal secretions and feces in swabs 
collected on days 0, 3, 7, 10 and 14 pc by RT-qPCR. High levels of virus excretion were 
detected between days 3 and 14 pc in animals from the control (G1) and inactivated-vaccine 
groups (G2) (Fig. 7D, E and F). Virus shedding was significantly lower in animals from 
live IM (G3)- and live IN (G4) groups (P < 0.01) when compared to both control (G1) and 
inactivated (G2) groups in oral and nasal secretions (Fig. 7D and E). Remarkably, no virus 
shedding was detected in feces in the live IM (G3)- and live IN (G4) group animals (Fig. 
7F). 
The association of NA responses (42 dpi/0 dpc) and levels of viremia/virus 
shedding (day 1 through 14 dpc) were evaluated in samples collected from control and 
immunized animals. A high negative correlation between NA levels and levels of viremia- 
(r = -0.856, 95% CI = -0.938 to -0.685, P < 0.001), virus shedding in oral- (r = -0.744, 95% 
CI = -0.885 to -0.478, P < 0.001), and nasal secretions (r = -0.756, 95% CI = -0.891 to -
0.497, P < 0.001) and feces (r = -0.797, 95% CI = -0.910 to -0.571, P < 0.001) was 
observed (Fig. 8A). We also assessed the correlations between T-cell responses and levels 
viremia/virus shedding.  Low to moderate negative correlation between proliferative CD4+ 
and CD8+ T cell responses and levels of viremia/virus shedding (oral, nasal and fecal) was 
observed. Additionally, moderate to high negative correlation between proliferative double 
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positive CD4+/CD8+ T cell responses and viremia/virus shedding was detected (Fig 8B, C 
and D).  
Neutralizing antibody responses post-challenge infection. The serological responses post-
challenge infection was evaluated by VN assays. Serum samples collected on days 0, 3, 7 
and 14 pc were tested by VN assays. As shown in Fig. 6A, all animals in control (G1) and 
inactivated (G2) group seroconverted post-SVA challenge infection, presenting a robust 
increase in the levels of NA antibodies. Levels of NA detected in control animals on days 
7, 10 and 14 pc were significantly higher than in inactivated (G2), live IM (G3) and live 
IN (G4) groups (Fig. 6A).  Notably, no increase in NA titers were detected in animals from 
the live IM (G3) and live IN (G4) groups after challenge infection (Fig. 6A).  
Protective responses elicited by immunization with rSVA mSacII lead to decreased viral 
load in tissues. Viral load was assessed in lymphoid tissues (tonsil, mediastinal and 
mesenteric lymph nodes) following challenge infection (day 14 pc) using RT-qPCR. 
Immunization with inactivated or live rSVA mSacII virus led to a marked decrease in viral 
load in all tissues tested (Fig. 9).  Significantly lower SVA genome copy numbers were 
detected in the tonsil of animals immunized with inactivated (G2, P < 0.05)-, live IM (G3, 
P < 0.05), or live IN (G4, P < 0.05) rSVA mSacII virus, when compared to control animals 
(G1) (Fig. 9A). No significant differences in SVA RNA copy number was observed 
between inactivated (G2)-, live IM (G3)-, live IN (G4)- rSVA mSacII immunized animals 
(Fig. 9A). Viral load in mediastinal or mesenteric lymph nodes were significantly lower in 
live IM (G3; P < 0.05)-, live IN (G4, P < 0.001)- rSVA mSacII immunized animals when 
compared to control animals (G1) (Fig. 9B and C). The levels of SVA load in animals in 
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the live IN (G4) group were lower with fewer animals being positive in all three tissues 
when compared to animals in G2 and G3 (Fig. 9). 
 The association between NA- and T cell responses with viral load in tissues (14 
dpc) was evaluated. Moderate-to-high negative correlations between NA levels and vial 
load in the tonsil (r = -0.569, 95% CI = -0.795 to -0.202, P < 0.01), mediastinal LN (r = -
0.711, 95% CI = -0.869 to -0.422, P < 0.001) and mesenteric LN (r = -0.761, 95% CI = -
0.894 to -0.507, P < 0.001) were observed (Fig. 10A). We also observed an association 
between T cell responses and tissue viral load.  Moderate negative correlation between 
CD8+ and CD4+CD8+ double positive T cells were observed (Fig 10B and C).  
Discussion 
 Here we generated an attenuated rSVA strain and assessed its safety and efficacy 
when administered as an inactivated/adjuvanted or live attenuated vaccine against 
heterologous SVA challenge in pigs. The rSVA mSacII was generated using reverse 
genetics and engineered to contain three nucleotide changes in the 5’UTR region (C→T) 
of the genome and one silent nt change (C→A) in the P1/VP4 coding region. The three 
nucleotides substitutions in the 5’UTR region (C→T) were derived from the low virulence 
SVA strain SVV001, while the change in the P1/VP4 region (position 942) was inserted to 
delete a SacII restriction site from the virus genome.  
Although originally designed with the intent of rescuing a virulent rSVA strain, in 
vitro characterization of the rSVA mSacII virus demonstrated lower viral yields and protein 
expression in infected cells when compared to the wt SVA SD15-26 virus. Most 
importantly, inoculation of finishing pigs with the rSVA mSacII virus did not result in overt 
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VD, and inoculated animals presented lower levels of viremia and virus shedding in oral, 
nasal secretions and feces when compared to animals inoculated the wt SVA SD15-26 
virus. These findings indicated that the rSVA mSacII virus was attenuated in pigs. The 
mechanism(s) of attenuation of rSVA mSacII was/were not investigated in our study, 
however, it is possible that the nucleotides changes introduced in the 5’UTR and/or in the 
P1 coding region may have affected the conformation of RNA secondary structures present 
in these regions of the virus genome (e.g. internal ribosomal entry site [IRES] or cis-active 
RNA elements [CRE], respectively) (24–26). Changes affecting the conformation of these 
RNA structures have been linked to impaired protein expression and/or picornavirus 
replication, thus resulting in decreased virus virulence and attenuated disease phenotype 
(27–29). Results here showing lower viral yields and reduced protein expression levels in 
rSVA mSacII infected cells support this hypothesis. However, additional studies are 
needed to dissect the precise molecular determinants that led to attenuation of the rSVA 
mSacII virus in pigs. Notably, despite its attenuated phenotype no significant differences 
in the levels of NA were observed between animals inoculated with rSVA mSacII or with 
the parental wt SVA SD15-26, demonstrating that rSVA mSacII retained its 
immunogenicity.  
Given the attenuated phenotype and the immunogenicity of the rSVA mSacII in 
pigs, the next step of our study was to assess the potential of this viral strain as a vaccine 
candidate for SVA. Previously we have shown that both antibody- and T cell responses are 
correlated with the control of SVA infection and peak antibody and T cell responses 
parallel with disease resolution (18). Thus, here we assessed the efficacy of inactivated- or 
live rSVA mSacII vaccine formulations against a heterologous SVA challenge. Following 
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immunization none of the animals presented clinical signs nor lesions of SVA, confirming 
efficient inactivation- (G2) and, most importantly, attenuation of the rSVA mSacII virus 
(G3 and G4). As expected, animals immunized with the live rSVA mSacII via the IM or 
IN routes excreted virus in nasal and oral secretions and in feces for 7-21 days post-
immunization. Restriction enzyme (Sac II) analysis of the P1 region from PCR amplicons 
obtained directly from serum and/or nasal secretions from immunized animals on day 3 
post-immunization confirmed the identity of the rSVA mSacII sequences during 
replication of the vaccine virus in pigs (data not shown). These results indicate that rSVA 
mSacII is a good vaccine candidate to prevent SVA in swine. Additional studies are 
required, however, to evaluate the genetic stability of this virus after passage/transmission 
among a cohort of immunized/commingled animals. 
The immune responses elicited by immunization with inactivated or live rSVA 
mSacII vaccine formulations were also evaluated. Notably, while robust neutralizing 
antibody responses were detected in all animals immunized with a single dose of the live 
rSVA mSAcII via the IM and the IN routes, animals immunized with the inactivated 
vaccine formulation presented a delayed NA response with several animals only 
seroconverting after the booster immunization on day 21 pi. Importantly, one dose of the 
live rSVA mSacII virus elicited significantly higher NA responses against SVA, than two 
doses of the inactivated rSVA mSacII vaccine formulation. Although a secondary humoral 
immune response was observed after the booster immunization with the inactivated rSVA 
mSacII vaccine, NA titers never reached the levels elicited by immunization with the live 
virus. This is likely a result of antigen amplification during replication of the live attenuated 
virus in immunized animals leading to a broader and more efficient stimulation of the 
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immune system. This was also evident at the T cell level, as recall stimulation of PBMCs 
from animals immunized with the live rSVA mSacII led to robust proliferative responses 
of CD4+, CD8+, CD4+CD8+ and γδ- T cells (CD4-CD8-).    
The association between the capacity of picornavirus vaccines to elicit virus-
specific immune responses and protection against challenge infection has been reported for 
several picornaviruses (22, 23, 30, 31). Neutralizing antibodies seem to be correlated with 
protection against most picornaviruses (22, 31–33), while the role of T cell responses is 
debatable with some studies showing the contribution of T cells to protection (34), while 
others demonstrate only partial protection (35). The protective efficacy of the rSVA mSacII 
vaccine formulations and the immune responses elicited by immunization with these 
vaccine candidates was investigated here following challenge of immunized animals with 
a virulent heterologous SVA strain (MN15-84-22 at 108.5 TCID50; day 42 post-
immunization) (Table 1). While 4 out of 6 (4/6) animals in the control group and 3/6 
animals in the inactivated vaccine group presented characteristic SVA lesions, none of the 
animals in the live IM and IN groups presented clinical signs or lesions compatible with 
SVA infection. Consistent with the clinical outcome post-challenge, the magnitude and 
extent of viremia and virus shedding in nasal and oral secretions and feces was significantly 
lower in animals immunized with the live rSVA mSacII virus via the IM or IN routes. 
Notably, no fecal excretion was detected in the live IM and IN groups following challenge 
infection. Additionally, animals in the IM and IN groups did not seroconvert after the 
challenge infection, whereas control animals and animals in the inactivated vaccine group 
presented anamnestic serological responses to the challenge virus. Together, these findings 
demonstrate solid protection of animals immunized with the live attenuated rSVA mSacII 
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virus against heterologous virus challenge. Immunization with the inactivated rSVA 
mSacII formulation, on the other hand, only elicited partial protection. These contrasting 
protective efficacies may potentially reflect significant differences in the levels of 
neutralizing antibodies and/or T cell responses elicited by live or inactivated virus 
immunization (Fig. 6). 
Recently the immunogenicity and protective efficacy of a cell culture derived 
inactivated SVA vaccine candidate was evaluated in pigs (22). This study demonstrated 
that animals immunized with a 2 µg-dose of the vaccine formulation developed higher 
titers of NA antibodies and were protected against homologous SVA challenge (22). 
Animals that received 1/3 or 1/9 of the vaccine dose, however, developed lower levels of 
NA antibodies and were only partially protected against challenge infection (22). Although 
a parallel between the levels/titers of neutralizing antibodies elicited by immunization and 
protection was observed in the present study and in the study by Yang and collaborators 
(22), studies with other picornaviruses, including FMDV, have shown that this correlation 
is not precise (22, 32, 35). While some animals presenting low NA titers can resist 
challenge infection, others will succumb and develop overt clinical disease (22, 32). Thus, 
defining protective antibody levels for picornaviruses is complex and it is complicated by 
the role of antibodies in opsonization and phagocytosis and by the potential involvement 
of T cells in protection against virus infection (22, 36).   
Viral load in tissues was also evaluated in our study as a measure of vaccine elicited 
protection. For this, SVA RNA present in lymphoid tissues, including tonsil and 
mediastinal- and mesenteric lymph nodes was quantified by real-time PCR. These tissues 
have been shown to harbor SVA with the tonsil potentially serving as one of the primary 
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sites for virus replication (17, 21). Results here show low amounts of SVA RNA in tonsil 
and mediastinal and mesenteric lymph nodes in animals from the live vaccine groups (Fig. 
9). Some animals did not present detectable levels of SVA RNA in the tonsil and many 
animals did not present detectable viral RNA in the lymph nodes. A lower frequency of 
positive animals was detected in the group immunized with the live rSVA mSacII via the 
IN route, suggesting a more effective role of local mucosal immunity in protection against 
SVA challenge when compared to systemic immunity elicited by parenteral administration 
of the inactivated or live vaccine formulations. The lower amounts of virus detected in 
tissues of animals in the live IM or live IN vaccine groups when compared to the viral load 
detected in inactivated group, may also be a result of increased T cell activity and virus 
clearance elicited by the live virus vaccine. Additional studies are needed, however, to 
characterize local mucosal immunity following IN immunization with SVA and to dissect 
the function of T cells in protection against SVA.  
  This study describes the development of an effective live attenuated rSVA vaccine 
candidate capable of providing solid protection against heterologous SVA challenge in 
pigs. A single dose of the live attenuated vaccine candidate administered via the IM or IN 
routes elicited protection to challenge with a virulent SVA strain, as evidenced by lack of 
clinical signs and lower levels of viremia, virus shedding and viral load in tissues. Given 
that currently there is only one SVA serotype circulating in the swine population worldwide 
(21), the live attenuated vaccine candidate developed here may represent a valuable tool to 
prevent and control SVA outbreaks.  
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Materials and Methods 
Viruses and cells. H1299 and BHK-21 cells were obtained from the American Type 
Culture Collection (ATCC-CRL 5803 and CCL-10, respectively). PK-15 cells were 
obtained from the Virology section at the Animal Disease Research and Diagnostic 
Laboratory (ADRDL). H1299 and PK-15 cells were maintained at 37oC with 5% CO2 in 
RPMI-1640 or MEM (Corning, NY), respectively supplemented with 10% fetal bovine 
serum (VWR, Chicago, IL) and 2 mM L-Glutamine (Corning, NY). Penicillin (100 U/mL) 
and streptomycin (100 µg/mL) were also added to culture media. 
SVA strain SD15-26 was isolated from swine presenting vesicular disease and has 
been previously characterized (17, 18). The challenge virus, SVA strain MN15-84-22, was 
isolated from swine presenting vesicular disease (9). For both wild type SVA strains, low-
passage (passage 4) viral stocks were amplified and titrated in H1299 cells and used in 
experiments described below. Recombinant rSVA mSacII virus was rescued in BHK-21 
and H1299 cells and amplified in PK15 cells as described below. 
Generation and rescue of rSVA mSacII virus. An infectious virulent cDNA close of SVA 
strain SD15-26 (pBrick-FLSVA-SD15-26) containing the full length SVA genome under 
control of a T7 RNA polymerase promoter was recently developed in our laboratory 
(Fernandes et al., unpublished data). This clone was used as a backbone to construct the 
rSVA mSacII virus here. In rSVA mSacII clone, four nucleotide changes were introduced 
in the virus genome. Three of those changes are in the 5’UTR (c→t, positions 29, 31 and 
32) and the fourth change consists of a silent nucleotide change (c→a) at position 942 (VP4 
coding region) of the rSVA genome (added to delete a SacII restriction endonuclease site). 
A synthetic DNA fragment (GenScript) containing these specific nucleotide changes was 
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cloned into the backbone of the rSVA plasmid (virus described above; pBrick-FLSVA-
SD15-26) using unique restriction endonucleases (NheI and SfiI) and standard cloning 
techniques. The resultant recombinant SacII mutant clone (pBRICK-rSVA mSacII) was 
amplified in Stable 2 cells (Life Technologies) and the purified plasmid DNA was 
linearized with NotI-HF (NEB) restriction enzyme, which digests the cDNA clone after the 
poly A tail. The linear pBRICK-rSVA mSacII DNA was used as template in in vitro 
transcription reactions using the MEGAscript™ T7 Transcription Kit (ThermoFisher 
Scientific) following the manufacturer’s instructions. Full-length viral genomic RNA was 
purified using standard phenol:chloroform purification and ethanol precipitation, and 
approximately 1 µg of viral RNA was transfected in BHK-21 cells using Lipofectamine™ 
RNAiMAX transfection reagent (ThermoFisher Scientific) according to the 
manufacturer’s instructions. At 48 h post-transfection cells were subjected to three freeze-
and-thaw cycles and the virus passaged two more times in H1299 cells. When cytopathic 
effect was observed, cells were fixed and rescue of rSVA mSacII virus was confirmed by 
immunofluorescence (IFA) using a rabbit polyclonal antibody against SVA.  
 The identity of the rSVA mSacII virus was confirmed by RT-PCR amplification of 
a fragment in the 5’ end of the SVA genome (primers sequences available upon request) 
followed by SacII restriction digestion of the PCR amplicon. Restriction digestion 
reactions were analyzed by agarose gel electrophoresis and the identity of rSVA mSacII 
was determined by lack of SacII digestion in the rSVA mSacII virus PCR amplicon. A 
PCR amplicon of wt rSVA SD15-26 was used as control. Additionally, complete genome 
sequencing of rSVA mSacII virus was used to confirm the identity and integrity of the 
virus genome using the Illumina MiSeq sequencing platform (17). 
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Growth curves. Replication kinetics of wt SVA SD15-26 and rSVA mSacII were assessed 
in vitro. H1299 and PK-15 cells were cultured in six-well plates, infected with both viruses 
at a multiplicity of infection (MOI) of 0.1 (multi-step growth curve) or 10 (single-step 
growth curve), and harvested at various time points post-infection (2, 4, 8, 12 and 24 h 
post-infection). Virus titers were determined for each time point using end-point dilution 
and the Spearman and Karber’s calculation method and expressed as TCID50/ml. 
Western blots. Western blot was performed to assess protein expression by the rSVA 
mSacII virus in comparison with wt SVA virus. For this, H1299 cells were infected with 
both viruses at a MOI of 10 and harvested at different time points post-infection (0, 2, 4, 
8, 12 and 24 h). Cells were lysed with M-PER mammalian protein extraction reagent 
(ThermoFisher Scientific) containing protease inhibitors. Approximately, 100 µg total 
protein extracts were mixed with Laemmli Buffer (to a final concentration of 1x; Bio-Rad, 
Hercules, CA) containing 5% β-mercaptoethanol and denatured at 95 oC for 10 min then 
loaded in 10% SDS-PAGE gel. Electrophoresis was performed at 90 volts for 90 min and 
proteins were transferred to nitrocellulose membranes and blocked with 5% skim-milk in 
1× phosphate-buffered saline (PBS) overnight at 4 oC. Nitrocellulose membranes were 
washed three times in 1×PBS containing 0.05% Tween 20 (PBST) and incubated with anti-
VP1 and anti-VP2 mouse monoclonal antibodies (1:1000) in 0.05% PBST for 2 hours at 
RT. Membranes were washed three times with 0.05% PBST. Secondary IRDye® 800CW 
Goat anti-Mouse IgG (H+L) (LI-COR Biosciences, Lincoln, NE) antibody was added to 
the membranes (1:15000 on 1% skim-milk on 0.05% PBST) and incubated for 1 hour at 
RT. Membranes were washed three times with PBST 0.05% and blots developed using a 
LI-COR® Odyssey® Fc Imaging system (LI-COR Biosciences, Lincoln, NE). 
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 The antigen load in both inactivated and live rSVA mSacII vaccine formulations 
was also assessed by western blots. For this, 20 µL of each vaccine formulation containing 
the rSVA mSacII virus suspension at 106 TCID50/mL were mixed with Laemmli Buffer 
(Bio-Rad, Hercules, CA) and subjected to SDS-PAGE and immunoblotting as described 
above. 
Animal pathogenesis study. The pathogenicity of the rSVA mSacII virus was investigated 
in pigs. For this, twelve 15-week old SVA-negative finishing pigs weighing approximately 
60 kg were randomly allocated in two experimental groups as follows: Group 1, wt SVA 
SD15-26- inoculated group (n = 6), and rSVA mSacII-inoculated group (n = 6). Animals 
from both groups were inoculated with virus suspensions containing 108.5 TCID50 via the 
oronasal route (5 mL orally and 5 mL intranasally [half into each nostril]). Animals were 
challenged on arrival at SDSU Animal Resource Wing (ARW). Animals received food and 
water ad libitum for the duration of the 14-day experiment.  
 Animals were monitored daily after inoculation for characteristic SVA clinical 
signs and lesions. Clinical signs and lesions were recorded, and individual daily lesion 
scores were attributed to each animal and total daily scores were calculated (21). Swabs 
(oral, nasal and rectal) and blood samples (serum and whole heparinized blood) were 
collected on days 0, 1, 3, 7, 10 and 14 pi. At necropsy on day 14 pi, tissues including heart, 
lungs, kidney, liver, small intestine, large intestine, thymus, spleen, mediastinal lymph 
node, mesenteric lymph node and tonsil were collected and stored at -80oC. Animal 
experiments were revised and approved by the SDSU Institutional Animal Care and Use 
Committee (approval number 16-002A). 
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Immunization-challenge experiment. The immunogenicity and protective efficacy of 
rSVA mSacII virus were evaluated in 3-week-old SVA-negative piglets. Animals were 
randomly allocated in four experimental groups: control (G1, received RPMI 1640, IM; n 
= 6), inactivated (G2, received BEI-inactivated rSVA mSacII vaccine; n = 6), live IM 
(G3, receiving rSVA mSacII by IM route; n = 6) and live IN (G4, received rSVA mSacII 
by IN route; n = 6). After a week of acclimation, animals were immunized with the 
corresponding candidate vaccines (2 mL) via the immunization routes described above 
and presented in Table 1. Inactivation of rSVA mSacII virus by BEI was performed as 
previously described (37), and a water-in-oil-in-water (W/O/W) emulsion was produced 
by shear-mixing equal volume of the MONTANIDETM ISA 201 VG oil adjuvant (1 mL, 
Seppic SA, Paris) with BEI inactivated virus (1 mL; 106 TCID50) at 31 
oC using syringes 
joined by a lure lock connector as recommended by the adjuvant manufacturer. The live 
rSVA mSacII vaccine consisted of 2 ml virus suspension (106 TCID50) in RPMI 1640 
medium. Animals in control and inactivated groups were immunized on day 0 and 
boosted on day 21 post-primary immunization, whereas animals in the live IM and live 
IN groups were immunized with a single vaccine dose on day 0.  
Animals were monitored daily for signs and lesions throughout the experiment. 
Oral, nasal and rectal swabs were collected on days 0, 3, 7, 14 and 21 pi. Blood was 
collected on days 0, 3, 5, 7, 14, 21, 28 and 35 pi. Serum separation and PBMC isolation 
were performed as previously described (18).  
A heterologous SVA strain (SVA MN15-84-22) (9) was used as challenge virus 
and animals in all groups were challenged on day 42 pi (or day 0 post-challenge; pc). Blood 
and swabs (oral, nasal and rectal) were collected on days 0, 3, 7, 10 and 14 pc and processed 
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and stored as above. All animals were euthanized on day 14 pc at the Animal Disease 
Research and Diagnostic Laboratory (ADRDL), SDSU. Tissues including tonsil and 
mediastinal and mesenteric lymph nodes were collected and stored at -80oC. Animal 
immunization-challenge experiments were reviewed and approved by the SDSU 
Institutional Animal Care and Use Committee (approval number 18-032A).   
RNA extraction and real-time PCR (RT-qPCR). Nucleic acid was extracted from serum, 
swabs and tissue samples using the Cador® Pathogen 96 kit (Indical Bioscience) and the 
QIAcube® HT (Qiagen) automated extractor following the manufacturer’s instructions. 
Swab samples were vortexed and cleared by centrifugation (10,000 × g for 5 min) and 200 
µL of cleared supernatant was used for nucleic acid extraction. Two hundred µL of serum 
was also used for nucleic acid extraction. For tissues, approximately 0.5 g of each tissue 
was minced using sterile scalpel, re-suspended in RPMI 1640 medium (10% w/v) and 
homogenized using a stomacher (2 cycles of 60s). Homogenized samples were then 
centrifuged at 14,000 × g for 2 minutes at room temperature and 200 µL of cleared 
supernatant was used for nucleic acid extraction using automated QIAcube HT (Qiagen). 
The presence of SVA RNA in samples was assessed using the SensiFASTTM Probe LO-
ROX One-Step kit (Bioline-Meridian Bioscience, MA, USA) and custom designed primers 
and probe (PrimeTime qPCR probe assays, Integrated DNA Technologies Inc., USA) 
targeting the SVA 3D gene. Primers and probe were designed using the PrimerQuest Tool 
(Integrated DNA Technologies Inc., USA). The probe and primers sequence are 5'-/56-
FAM/CAGGAACAC/ZEN/TACTCGAGAAGCTGCAA/3IABkFQ/-3', 5'- 
GAAGCCATGCTCTCCTACTTC-3' and 5'- GGGTGCATCAATCTATCATATTCTTC-
3' respectively. Amplification and detection were performed with an Applied Biosystems 
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7500 real time PCR system under following conditions: 10 minutes at 45oC for reverse 
transcription, 2 minutes at 95 oC for polymerase activation and 40 cycles of 5 seconds at 
95oC for denaturation and 30 seconds at 60 oC for annealing and extension. A standard 
curve was established by using SVA SD15-26 virus of titer 107.88 TCID50/mL and 
preparing 10-fold serial dilutions from 10-1 to 10-10. Relative viral genome copy numbers 
were calculated based on the standard curve determined using the four- parameter logistic 
regression model function within MasterPlex Readerfit 2010 software (Hitachi Software 
Engineering America, Ltd., San Francisco, CA). The amount of viral RNA detected in 
samples were expressed as log10 (genome copy number)/mL. 
Neutralization assays. Neutralizing antibody (NA) responses elicited by the vaccine 
candidates and pc were assessed using a virus neutralization assay as previously described 
(17, 18). NA titers were expressed as log2 (reciprocal of highest serum dilution capable of 
completely inhibiting SVA infection). All assays were performed in triplicate including 
positive and negative control in all test plates. 
PBMC recall stimulation and Flow cytometry. PBMC recall stimulation was performed as 
previously described (18). Briefly, PBMCs were thawed and stained with 2.5 µM 
carboxyfluorescein succinimidyl ester (CFSE; in PBS) according to the manufacturer’s 
instruction (BD Biosciences). CFSE-stained cells were seeded at a density of 5 × 105 
cells/well in 96-well plates, rested for 4 hours and stimulated as follows: UV-inactivated 
SVA SD15-26 (multiplicity of infection [MOI] = 2) and recombinant purified VP2 protein 
(1 µg/mL). Concanavalin A (ConA; 5 µg/mL) plus phytohemagglutinin (PHA; 5 µg/mL) 
(both from Sigma-Aldrich, St. Louis, MO), or cRPMI alone were used as positive and 
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negative controls in all assays, respectively. After stimulation, the cells were incubated for 
5 days at 37 °C with 5% CO2.  
Antigen-specific T-cell responses were assessed by flow cytometric analysis. T-
cell phenotypes were determined using the various swine-specific antibodies as previously 
described (18). Single-stain and fluorescence-minus-one (FMO) controls were included in 
all assays. All flow cytometry data were acquired with an Attune NxT flow cytometer 
(Thermo Fisher Scientific) and analyzed using FlowJo v.10 software (TreeStar, San Carlos, 
CA). The percentage of responding cells was calculated as the percentage of total T cells 
(live CD3+ cells). 
Statistical analysis. Statistical analysis was performed by analysis of variance (ANOVA) 
followed by Tukey’s multiple comparison test. Normality were checked before performing 
any tests. To assess the association of neutralizing antibody titers and/or T-cell responses 
between levels of viremia, virus shedding and viral load in tissues, Spearman rank 
correlation was used. Statistical analysis and data visualization were performed using 
GraphPAD Prism 8.0.1(244) software (GraphPAD Software Inc., La Jolla, CA). 
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Table 1. Animal immunization/challenge experimental design. 
Group (n) Treatment Dose Route Immunization day Challengeb 
1 (n = 6) Control 2 mL RPMI IM 0 and 21 dpi 
SVA 
MN15-84-
22 108.5 
TCID50 at 
42 dpi 
2 (n = 6) Inactivated 
(BEI) 
SVAa 
106 TCID50 
in 2 mL 
IM 0 and 21 dpi 
3 (n = 6) Live 
attenuated 
rSVA 
mSacII 
106 TCID50 
in 2 mL  
IM 0 dpi 
4 (n = 6) Live 
attenuated 
rSVA 
mSacII 
106 TCID50 
in 2 mL 
IN 0 dpi 
a. Adjuvant: Seppic Montanide™ ISA 201 (1:1) 
b. Animals were challenged oronasally with 10 mL of virus inoculum (26).  
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Fig 1. Characterization of the recombinant rSVAmSacII virus in vitro. (A) Restriction 
digestion with SacII enzyme of PCR amplicon of the P1 region of SVA genome. Agarose 
gel image shows digestion of P1-amplicon in wt SVA SD15-26 but not in rSVA mSacII. 
Undigested PCR products were used as controls. (B) Multi-step or (C) single-step growth 
curves. H1299 cells were infected with (B) 0.1 and (C) 10 MOI of wt SVA SD15-26 and 
rSVA mSacII and virus titers were determined at 2, 4, 8, 12 and 24 hours post-infection; 
Error bars represent SEM calculated based on results of four independent experiments (P-
values were determined by unpaired t-test; **, P < 0.01; ***, P < 0.001). Western blot to 
assess SVA-VP1 and VP2 protein expression in (D) wt SVA SD15-26 and (E) rSVA 
mSacII infected cells. H1299 cells were infected with an MOI of 10 of each virus harvested 
on the indicated time points and subjected to western blots using a VP1- or VP2-specific 
mAb.   
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Fig 2. The recombinant rSVA mSacII is attenuated in swine. (A) Clinical outcome post-
inoculation of wt SVA SD15-26 or rSVA mSacII viruses. Vesicular lesions were observed 
on the snout and feet of animals infected with wt SVA SD15-26 but not in animals infected 
with rSVA mSacII. (B) Total daily clinical scores post-infection in pigs. A score of 1 was 
attributed daily to each feet or snout presenting vesicular lesions for a total score of 5 per 
animal per day. (C) Viremia levels as determined by RT-qPCR in serum samples collected 
at the indicated times post-infection. Virus shedding in oral secretions (D), nasal secretions 
(E) or feces (F) as determined by RT-qPCR on swabs collected on indicated times post-
infection (P-values were determined by unpaired t-test; **, P < 0.01; ***, P < 0.001). 
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Fig 3. Viral load in tissues and serological responses post-infection in swine (A) Viral load 
in tissues was determined by RT-qPCR in several tissues collected on day 14 post-
infection. (B) Neutralizing antibody titers in both virus infected groups. (Data represent 
group means ± SEMs). 
 
 
 
Fig 4. Antigen load in live and inactivated vaccine formulations. Western blot 
demonstrating similar levels of capsid VP1 and VP2 proteins in both live and inactivated 
vaccines. Approximately 20 µl of each vaccine preparation were subjected SDS-PAGE, 
transferred to a nitrocellulose membrane and probed with anti-SVA-VP1 and -VP2 specific 
monoclonal antibodies.  
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Fig 5. Clinical and virologic outcomes after immunization. Twenty-four four-week old 
piglets were randomly allocated to four experimental groups (n = 6) and sham-immunized 
or immunized with inactivated or live (IM or IN) rSVA mSacII vaccine formulations. (A) 
Clinical outcome following immunization showing no lesions in immunized animals. (B) 
Total clinical scores following immunization. (C) Viremia levels determined in serum by 
RT-qPCR at the indicated time points post-immunization. Virus shedding in oral secretions 
(D), nasal secretions (E) and feces (F) as determined by RT-qPCR collected from 
immunized animals at the indicated times post-immunization. *a,b,c,d,e,f indicates 
significant difference between groups as follows: a. Control vs. Inactivated, b. Control vs. 
Live IM, c. Control vs. Live IN, d. Inactivated vs. Live IM, e. Inactivated vs. Live IN and 
f. Live IM vs. Live IN  at P < 0.05 (Data represent group means ± SEMs. P values were 
determined by Tukey’s multiple comparison test). 
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Fig 6. Immune responses elicited by immunization and/or challenge infection. (A) Virus 
neutralizing antibody responses as determined by VN assays performed in serum samples 
collected at the indicated times post-immunization and post-challenge. (B) 
Carboxyfluorescein succinimidyl ester (CFSE) proliferation assay performed in PBMCs 
obtained on day 42 pi (day of challenge). Cells stimulated with UV-inactivated SVA 
(MOI=1) for 5 days and proliferative responses of major swine T cell subsets were 
determined by flow cytometry. (B) Carboxyfluorescein succinimidyl ester (CFSE) 
proliferation assay performed in PBMCs obtained on day 42 pi (day of challenge). Cells 
stimulated with recombinant SVA VP2 protein (1µg/mL) for 5 days and proliferative 
responses of major swine T cell subsets were determined by flow cytometry. Proliferative 
T cells were expressed as percent of total CD3+ T cells on each sample. (Data represent 
group means ± SEMs. P values were determined by Tukey’s multiple comparison; *, P < 
0.05) 
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Fig 7. Clinical and virologic outcomes after heterologous SVA challenge. Animals in all 
groups were challenged oronasally with SVA MN15-84-22 (108.5 TCID50). (A) Clinical 
outcome following immunization showing no lesions in immunized animals. (B) Total 
clinical scores following immunization. (C) Viremia levels determined in serum by RT-
qPCR at the indicated time points post-immunization. Virus shedding in oral secretions 
(D), nasal secretions (E) and feces (F) as determined by RT-qPCR collected from 
immunized animals at the indicated times post-immunization. *a,b,c,d,e,f indicates 
significant differences between groups as follows: a. Control vs. Inactivated, b. Control vs. 
Live IM, c. Control vs. Live IN, d. Inactivated vs. Live IM, e. Inactivated vs. Live IN and 
f. Live IM vs. Live IN at P <0.05. (Data represent group means ± SEMs. P values were 
determined by Tukey’s multiple comparison). 
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Fig 8. Correlations between neutralizing antibody titers and proliferative T-cell responses 
with viremia and virus shedding. (A) Correlation between the levels neutralizing antibody 
(NA) titers at day 42 pi (day of challenge) with levels of viremia, virus shedding in oral 
secretions, nasal secretions and feces with post challenge infection (days 43-63 pi). (B) 
Correlation of CD4+ T-cell proliferation at day 42 pi (day of challenge) with levels of 
viremia, virus shedding in oral secretions, nasal secretions and feces post challenge 
infection (days 43-63 pi). (C) Correlation of CD8+ T-cell proliferation at day 42 pi (day of 
challenge) with the levels of viremia, virus shedding in oral secretion, nasal secretion and 
fecal swab post challenge infection (days 43-63 pi). (D) Correlation of CD4+CD8+ T-cell 
proliferation at day 42 pi (day of challenge) with the levels of viremia, virus shedding in 
oral secretions, nasal secretions and feces post challenge infection (days 43-63 pi). R values 
and statistics for each correlation are shown in the graphs (95% CI). 
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Fig 9. Viral load in tissues. Virus load in the (A) tonsil, (B) mediastinal lymph node, and 
(C) mesenteric lymph node as determined by RT-qPCR on tissues collected at necropsy on 
day 14 post-challenge. (Data represent group means ± SEMs. P values were determined by 
Tukey’s multiple comparison; *, P < 0.05; **, P < 0.01; ***, P < 0.001). 
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Fig 10. Correlations between neutralizing antibody titers and T-cell responses with viral 
load in tissues. (A) Correlation between NA antibody titers at day 42 pi (day of challenge) 
with viral load in tonsil, mediastinal lymph node and mesenteric lymph node measured on 
day 63 pi (day of necropsy). (B) Correlation of CD8+ T-cell proliferation at day 42 pi (day 
of challenge) with viral load in tonsil, mediastinal lymph node and mesenteric lymph node 
on day 63 pi (day of necropsy). (C) Correlation of CD4+CD8+ T-cell proliferation at day 
42 pi (day of challenge) with viral load in tonsil, mediastinal lymph node and mesenteric 
lymph node on day 63 pi (day of necropsy). R values and statistics for each correlation are 
shown in the graphs (95% CI). 
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The goal of this study was to develop a vaccine against Senecavirus A (SVA) and evaluate 
its effectiveness in pigs. The major conclusions from our studies are: 
1. The recombinant SVA mSacII virus is attenuated in pigs as evidenced by absence 
of clinical signs in inoculated animals. 
2. Virus neutralizing antibody responses elicited against the recombinant virus are 
similar to that elicited by the wild type virus. 
3. SVA can be inactivated by aziridine compound binary ethylenimine (BEI) at a 1.5 
mM concentration, which can be used as inactivated vaccine when administered 
with adjuvant. 
4. Virus neutralizing antibody (NA) titer is observed 3 days post-immunization when 
immunized with live recombinant virus but 14 days post-immunization when 
immunized with inactivated virus, which never reached same level as live 
vaccinated group. 
5. Cell mediated immune response as shown by CD3+ T-cell and its sub-population 
CD4+, CD8+, CD4+/CD8+ and γδ-T cell were more proliferated in live vaccinated 
group than inactivated and control animals after PBMC recall stimulation. 
6. After heterologous SVA challenge, animals immunized with live vaccine did not 
show any clinical signs, low viremia, less virus shedding and none to very low 
tissue viral load compared to inactivated vaccine and control groups. 
Our study developed a live attenuated vaccine against Senecavirus A which could 
have application to control SVA infection in the field. 
Conclusions 
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